Aclaris Therapeutics, INC Form 4 insider transactions

Director Braden Michael Leonard reports purchasing additional shares of Aclaris Therapeutics, Inc. (ACRS) through BML Investment Partners, L.P.

Director Leonard Michael Braden reports acquisition of Aclaris Therapeutics shares through BML Investment Partners, L.P.

Director Leonard Braden Michael reports purchasing additional shares of Aclaris Therapeutics through BML Investment Partners, L.P.

Neal Walker, Interim President and CEO of Aclaris Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Director Leonard Braden Michael reports acquiring additional shares of Aclaris Therapeutics, Inc. through BML Investment Partners, L.P.

Director Leonard Michael Braden reports purchasing additional shares of Aclaris Therapeutics, Inc. through BML Investment Partners, L.P.

Director Leonard Michael Leonard reports purchasing additional shares of Aclaris Therapeutics, Inc. (ACRS) common stock through BML Investment Partners, L.P.

Director William D. Humphries of Aclaris Therapeutics acquired stock options and restricted stock units on June 6, 2024, as part of the company's non-employee director compensation policy.

Director Vincent Milano of Aclaris Therapeutics acquired stock options and restricted stock units on June 6, 2024, according to a Form 4 filing with the SEC.

Director Christopher P. Molineaux reports the acquisition of stock options and restricted stock units in Aclaris Therapeutics, Inc.

Director Maxine Gowen acquired shares of Aclaris Therapeutics through stock options and restricted stock units, according to a recent SEC filing.

Director Andrew Schiff acquired shares of Aclaris Therapeutics through stock options and restricted stock units, according to a recent SEC filing.

Director Anand Mehra acquired stock options and restricted stock units in Aclaris Therapeutics, according to a Form 4 filing.

Neal Walker, Interim President and CEO of Aclaris Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Bryan M. Reasons, a director of Aclaris Therapeutics, Inc., exercised stock options and acquired 4,660 shares of common stock on June 1, 2024.

Director Andrew Powell reports the vesting of 4,660 restricted stock units convertible to common stock in Aclaris Therapeutics.

Director Vincent Milano of Aclaris Therapeutics reports the vesting and disposal of 4,660 restricted stock units on June 1, 2024.

Christopher P. Molineaux, a director at Aclaris Therapeutics, Inc., exercised stock options on June 1, 2024, resulting in the acquisition of 4,660 shares of common stock.

Director William Humphries of Aclaris Therapeutics, Inc. reports the vesting of restricted stock units and subsequent ownership of common stock.

Director Maxine Gowen reports the vesting of 4,660 restricted stock units convertible to common stock in Aclaris Therapeutics.

Director Anand Mehra of Aclaris Therapeutics reports the vesting of restricted stock units and subsequent disposition of shares.

Director Andrew Schiff reports a transaction involving Aclaris Therapeutics common stock, including the vesting of restricted stock units and shares held indirectly through Aisling Capital IV, LP.

Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units related to tax obligations and vesting.

Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock related to restricted stock units.

Interim President and CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units on March 1, 2024.

Joseph Monahan, Chief Scientific Officer of Aclaris Therapeutics, reports multiple transactions involving common stock and restricted stock units.

Kevin Balthaser, CFO of Aclaris Therapeutics, reports multiple transactions involving common stock and restricted stock units.

Director Andrew Kenneth William Powell increased his holdings in Aclaris Therapeutics through open market purchases.